Aridhia and Great Ormond Street Hospital sign 10-year deal

Aridhia, the cloud-based data analysis platform provider, has agreed a new ten-year deal with Great Ormond Street Hospital NHS Foundation Trust (GOSH). A spin-out from NHS Scotland that was originally supported and developed with SHIL, Aridhia will deliver the research and innovation component of the Trust’s multi-year digital transformation programme, demonstrating how successful innovations from within NHS Scotland contribute to real-world improvements in patient care.

Designed to enhance the way researchers access and analyse data in a secure and reproducible way, Aridhia's AnalytiXagility cloud-based data analysis programme enables research teams to rapidly access and extract value from a rich source of data in order to accelerate the translation of pioneering research into clinical practice.

Under the agreement, the Trust will adopt the ‘Ecosystem’ edition of AnalytiXagility. Functioning as the Trust’s digital research environment, AnalytiXagility will be used to enable, accelerate and transform the way GOSH manages its research projects. The service will be integrated with the Trust’s new Electronic Patient Record system.

Chris Roche, CEO of Aridhia, said: “Great Ormond Street Hospital is world-renowned and it is an honour to be given the opportunity to support such extraordinary researchers deliver ground-breaking research across multiple clinical domains. For Great Ormond Street to select AnalytiXagility after a rigorous 12-month procurement process is a great endorsement of our vision to accelerate clinical research.”

“The Trust was seeking a secure, scalable research platform that would allow their teams to collaborate on analysis and deliver rapid, auditable and reproducible results. AnalytiXagility satisfies these requirements. We are very much looking forward to working with them on this next stage of their research journey.”

Dr Peter Steer, Chief Executive, Great Ormond Street Hospital for Children Foundation Trust said: “We look forward to working with Aridhia to develop an innovative platform which will transform the way we undertake and collaborate on research. This will allow us to bring more lifesaving treatments to children with rare diseases in the UK and worldwide.”